FEATURES

Can Modifying Microbial Diversity Change Outcomes Following Allogeneic HSCT?

By

Some studies have found a link between intestinal microbiota composition and development of acute graft-versus-host disease.

Expert Perspective: The Role of Ibrutinib and Venetoclax in Chronic Lymphocytic Leukemia

By Prithviraj Bose, MD

Hematology Advisor asked Prithviraj Bose, MD, to discuss the latest research on treatment options for CLL presented at the ASH 2018 Annual Meeting.

Updated Clinical Practice Guidelines for Venous Thromboembolism: Pregnant and Pediatric Patients

By

In this 3-part series, Hematology Advisor spoke with experts about the revisions to the ASH clinical practice guidelines for venous thromboembolism.

Researchers Report Early Clinical Promise for Macrophage Checkpoint Blockade

By

A doublet immunotherapy regimen incorporating the investigational mAb Hu5F9-G4 shows clinical activity in patients with relapsed/refractory non-Hodgkin lymphoma.

Updated Clinical Practice Guidelines for Venous Thromboembolism: Treatment Strategies

By

In this 3-part series, Hematology Advisor spoke with experts about the revisions to the ASH clinical practice guidelines for venous thromboembolism.

Updated Clinical Practice Guidelines for Venous Thromboembolism: Diagnosis and Prophylaxis

By

In this 3-part series, Hematology Advisor spoke with experts about the revisions to the ASH clinical practice guidelines for venous thromboembolism.

Clinical Significance of Aspirin and NSAID Antiplatelet Interactions

By

Concomitant use of aspirin and NSAIDs gives rise to a pharmcodynamic interaction that may interfere with aspirin's antiplatelet effects.

Clinicians Face Uncertainties in Treating Older Patients With Hodgkin Lymphoma

By

A lack of research focusing primarily on older patients with Hodgkin lymphoma has led to an unmet need for effective, less toxic treatment in this population.

Advances in Treatment and Prevention of Hemophilia A: Takeaways From the 2018 ASH Annual Meeting

By Bryant Furlow

Research presented at the 2018 ASH Annual Meeting provided insights into the role of factor VIII as a therapeutic agent for severe hemophilia A.

CD19 CAR T-Cell Therapies: "Expect an Evolution"

By Bryant Furlow

"CD19 CAR therapy has paved the way for a new field of medicine based on the genetic instruction of T-cell responses," according to Dr Michel Sadelin.

High Risk of Thrombosis in Myeloproliferative Neoplasms, Underlying Cause Still Unclear

By

The prevalence of thrombotic events in patients with myeloproliferative neoplasms can be as high as 39% in some cases.

Controversy Continues Over Relationship Between VTE and Testosterone Therapy

By

Current clinical data are insufficient to confirm or deny the potential association between risk for VTE and testosterone therapy.

Standard Methodology Needed to Evaluate Pruritus in Cutaneous T Cell Lymphoma

By

Though the majority of patients with cutaneous T cell lymphomas experience pruritus, the pathophysiology of the symptom is relatively unclear.

Prognostic Value of Minimal Residual Disease in Indolent Lymphomas

By

Novel molecular technologies for detecting minimal residual disease may offer prognostic value for patients with indolent lymphomas.

Mixed Evidence on the Role of Vitamin D in Hematopoietic Stem Cell Transplantation

By

Recent research suggests that vitamin D deficiency may negatively influence outcomes after hematopoietic stem cell transplantation.

Novel Management Strategies for Myeloma Bone Disease

By

Therapeutic options for myeloma bone disease include bisphosphonates, immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies.

Managing Atrial Fibrillation in Patients With Beta Thalassemia Major

By

Patients with beta thalassemia major may be at higher risk for atrial fibrillation, creating a need for attentive clinical management.

Management of Venous Thrombosis in Unusual Sites

By

The incidence, pathophysiology, provoking factors, and recommended treatments for several types of unusual thrombosis were summarized in a review article.

Andexanet Alfa and the Role of Reversal Agents for Factor Xa Inhibitors

By

Andexanet alfa is the first anticoagulant reversal agent to receive global US FDA approval for patients with life-threatening or uncontrolled bleeding.

A New Genomic Dataset May be a Significant Step Forward in Combating Acute Myeloid Leukemia

By

A dataset comprising 672 tumor specimens collected from 562 patients describes both genetic and functional information about the biology of AML.

SIGN UP FOR FREE E-NEWSLETTERS